Active Pharmaceutical Ingredients Market Growth Report, 2032

Active Pharmaceutical Ingredients Market - By Therapeutic Category (Oncology, Infectious Diseases, Anti-Diabetics, CNS & Anesthesia), By Synthesis (Chemical Based API, Biological API, HPAPI), By Contract Outsourcing, By Application, By Drug & Forecast, 2023-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Methodology

1.2&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; working

1.3.1&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.6&nbsp;&nbsp;&nbsp; Data validation

1.7&nbsp;&nbsp;&nbsp; Data sources

1.7.1&nbsp;&nbsp;&nbsp; Primary

1.7.2&nbsp;&nbsp;&nbsp; Secondary

1.7.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.7.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Active Pharmaceutical Ingredients industry 3600 synopsis, 2018-2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Therapeutic category trends

2.1.3&nbsp;&nbsp;&nbsp; Synthesis type trends

2.1.4&nbsp;&nbsp;&nbsp; Contract outsourcing type trends

2.1.5&nbsp;&nbsp;&nbsp; Application trends

2.1.6&nbsp;&nbsp;&nbsp; Drug type trends

2.1.7&nbsp;&nbsp;&nbsp; Regional trends

Chapter 3&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry landscape, 2018-2032 (USD Million)

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Growing prevalence of chronic diseases

3.2.1.2&nbsp;&nbsp;&nbsp; Rising drug research and development activities

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing demand for generics

3.2.1.4&nbsp;&nbsp;&nbsp; Increasing uptake of biopharmaceuticals

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Unfavourable drug price control policies

3.2.2.2&nbsp;&nbsp;&nbsp;High manufacturing costs

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By therapeutic category trends

3.3.2&nbsp;&nbsp;&nbsp; By synthesis type trends

3.3.3&nbsp;&nbsp;&nbsp; By contract outsourcing type trends

3.3.4&nbsp;&nbsp;&nbsp; By application trends

3.3.5&nbsp;&nbsp;&nbsp; By drug type trends

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Technology landscape

3.6&nbsp;&nbsp;&nbsp; Supply chain analysis

3.7&nbsp;&nbsp;&nbsp; key market trends

3.8&nbsp;&nbsp;&nbsp; Pipeline analysis

3.9&nbsp;&nbsp;&nbsp; Regulatory landscape

3.9.1&nbsp;&nbsp;&nbsp; U.S.

3.9.2&nbsp;&nbsp;&nbsp; Europe

3.9.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.10&nbsp;&nbsp;&nbsp; Vendor matrix analysis

3.11&nbsp;&nbsp;&nbsp; API manufacturing trends

3.12&nbsp;&nbsp;&nbsp; Overview of API Production

3.12.1&nbsp;&nbsp;&nbsp; Share of supply in (%) Total European Demand in Tons

3.12.2&nbsp;&nbsp;&nbsp; Overview of CEPS, APIs and Manufacturers By Region (2000-2020)

3.12.3&nbsp;&nbsp;&nbsp; Overview of development of the number of valid CEPS (2000 -2020)

3.12.4&nbsp;&nbsp;&nbsp; Overview of global distribution of currently valid CEPS (2020)

3.12.5&nbsp;&nbsp;&nbsp; Analyst insights

3.13&nbsp;&nbsp;&nbsp; Policy landscape

3.13.1&nbsp;&nbsp;&nbsp; China

3.13.2&nbsp;&nbsp;&nbsp; India

3.14&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.15&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2021

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2021

4.3&nbsp;&nbsp;&nbsp; Strategy dashboard, 2021

4.4&nbsp;&nbsp;&nbsp; Strategy landscape

Chapter 5&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients Market, By Therapeutic Category

5.1&nbsp;&nbsp;&nbsp; Key therapeutic category trends

5.2&nbsp;&nbsp;&nbsp; Oncology

5.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.3&nbsp;&nbsp;&nbsp; Infectious diseases

5.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.4&nbsp;&nbsp;&nbsp; Anti-diabetics

5.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.5&nbsp;&nbsp;&nbsp; CNS &amp; anesthesia

5.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.6&nbsp;&nbsp;&nbsp; Cardiovascular diseases

5.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.7&nbsp;&nbsp;&nbsp; Biologics

5.7.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.8&nbsp;&nbsp;&nbsp; Others

5.8.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients Market, By Synthesis Type

6.1&nbsp;&nbsp;&nbsp; Key synthesis type trends

6.2&nbsp;&nbsp;&nbsp; Chemical based API

6.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

6.3&nbsp;&nbsp;&nbsp; Biological API

6.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

6.4&nbsp;&nbsp;&nbsp; Highly potent API (HPAPI)

6.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients Market, By Contract Outsourcing Type

7.1&nbsp;&nbsp;&nbsp; Key contract outsourcing type trends

7.2&nbsp;&nbsp;&nbsp; CDMO

7.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

7.3&nbsp;&nbsp;&nbsp; CMO

7.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients Market, By Application

8.1&nbsp;&nbsp;&nbsp; Key application trends

8.2&nbsp;&nbsp;&nbsp; Humans

8.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

8.3&nbsp;&nbsp;&nbsp; Veterinary

8.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 9&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients Market, By Drug Type

9.1&nbsp;&nbsp;&nbsp; Key drug type trends

9.2&nbsp;&nbsp;&nbsp; Prescription

9.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

9.3&nbsp;&nbsp;&nbsp; OTC

9.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 10&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients Market, By Region

10.1&nbsp;&nbsp;&nbsp; Key regional trends

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp; U.S.

10.2.2&nbsp;&nbsp;&nbsp; Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp; Switzerland

10.3.2&nbsp;&nbsp;&nbsp; France

10.3.3&nbsp;&nbsp;&nbsp; Italy

10.3.4&nbsp;&nbsp;&nbsp; Germany

10.3.5&nbsp;&nbsp;&nbsp; UK

10.3.6&nbsp;&nbsp;&nbsp; Spain

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp; China

10.4.2&nbsp;&nbsp;&nbsp; Japan

10.4.3&nbsp;&nbsp;&nbsp; India

10.4.4&nbsp;&nbsp;&nbsp; Australia

10.4.5&nbsp;&nbsp;&nbsp; South Korea

10.4.6&nbsp;&nbsp;&nbsp; Vietnam

10.4.7&nbsp;&nbsp;&nbsp; Indonesia

10.4.8&nbsp;&nbsp;&nbsp; Thailand

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp; Brazil

10.5.2&nbsp;&nbsp;&nbsp; Mexico

10.5.3&nbsp;&nbsp;&nbsp; Argentina

10.5.4&nbsp;&nbsp;&nbsp; Colombia

10.5.5&nbsp;&nbsp;&nbsp; Chile

10.5.6&nbsp;&nbsp;&nbsp; Peru

10.6&nbsp;&nbsp;&nbsp; MEA

10.6.1&nbsp;&nbsp;&nbsp; South Africa

10.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

10.6.3&nbsp;&nbsp;&nbsp; UAE

10.6.4&nbsp;&nbsp;&nbsp; Qatar

10.6.5&nbsp;&nbsp;&nbsp; Bahrain

10.6.6&nbsp;&nbsp;&nbsp; Egypt

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

11.2&nbsp;&nbsp;&nbsp; Aarti Drugs Ltd

11.3&nbsp;&nbsp;&nbsp; Biocon Ltd.

11.4&nbsp;&nbsp;&nbsp; Qilu Pharmaceutical Co., Ltd.

11.5&nbsp;&nbsp;&nbsp; Divi&#39;s Laboratories Limited

11.6&nbsp;&nbsp;&nbsp; EUROAPI

11.7&nbsp;&nbsp;&nbsp; Hikal Ltd.

11.8&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd

11.9&nbsp;&nbsp;&nbsp; Cipla Ltd.

11.10&nbsp;&nbsp;&nbsp; Neuland Laboratories Ltd.

11.11&nbsp;&nbsp;&nbsp; Aurobindo Pharma Ltd

11.12&nbsp;&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd.

11.13&nbsp;&nbsp;&nbsp; Dr. Reddy&rsquo;s Laboratories Ltd

11.14&nbsp;&nbsp;&nbsp; Pfizer, Inc

11.15&nbsp;&nbsp;&nbsp; Solara Active Pharma

11.16&nbsp;&nbsp;&nbsp; Alivira Animal Health Ltd

11.17&nbsp;&nbsp;&nbsp; SUANFARMA

11.18&nbsp;&nbsp;&nbsp; Procyon Life Sciences

11.19&nbsp;&nbsp;&nbsp; NGL Fine-Chem Ltd

11.20&nbsp;&nbsp;&nbsp; Ofichem Group 
&nbsp;

Active Pharmaceutical Ingredients Market

Get a free sample of this report